Brief: Cleave Therapeutics Licenses First-In-Class Vcp/P97 Inhibitor Cb-5339 To Casi Pharmaceuticals For Greater China Region
08/03/2021 13:40
March 8 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CLEAVE THERAPEUTICS LICENSES FIRST-IN-CLASS VCP/P97
INHIBITOR
CB-5339 TO CASI PHARMACEUTICALS FOR GREATER CHINA REGION
* CASI PHARMACEUTICALS INC - CLEAVE AND CASI WILL DEVELOP
CB-5339
IN BOTH HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS
* CASI PHARMACEUTICALS - CLEAVE WILL RECEIVE $5.5 MILLION
UPFRONT
AND IS ELIGIBLE TO RECEIVE UP TO $74 MILLION IN DEVELOPMENT AND
COMMERCIAL MILESTONE PAYMENTS
Source text for Eikon: ID:nPn1dtKw0a
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary